Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial fibrillation at moderate-to-high risk ...

A global commission presents a nuanced approach to defining clinical obesity as a chronic illness resulting from the effect of excess adiposity on organ and tissue function. Use of once-weekly ...

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

A mid-stage trial testing abelacimab from Anthos Therapeutics in patients with atrial fibrillation was stopped early due to an overwhelming reduction in bleeding compared to the rate seen in ...

Their trial, known as AZALEA-TIMI 71, focused on a drug called abelacimab. The findings, published in the New England Journal of Medicine, revealed that abelacimab significantly reduces bleeding ...

Patients coping with atrial fibrillation and using an experimental blood-thinning drug, abelacimab, experienced significantly fewer bleeding incidents compared to those on standard treatments, a ...

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes than patients receiving a standard-of-care blood thinner, a new study has ...

Participants were randomized and administered monthly injections of 150 mg abelacimab, 90 mg abelacimab, or standard dosing of rivaroxaban (20 mg or 15 mg in dose reduced patients). The team found ...